Amylinomimetics are important adjunctive drugs for treating type 1 diabetes (T1D). Here we describe the amylin analog BZ043 and its potential to be mixed with insulin glargine (GLAR) in a fixed combination (FC). The effect of BZ043 over fed glycemia, either alone or co-administered with GLAR, was investigated in rats with streptozotocin-induced diabetes (STZ). Fasted STZ rats (3 h) received a single treatment of BZ043 (0.15, 0.6 or 1.2 mg/kg), GLAR (1.5 IU/rat), or BZ043 plus GLAR (separate injections), and then had free access to food (5% glucose rich) and water. BZ043 dose-proportionally prevented meal-induced increase of glycemia and the co-treatment (0.6 or 1.2 mg/kg) with GLAR restored normoglycemia (100 mg/dL) without abrupt variations of glycemia (Figure. 1A), as further shown by comparison of the area under the blood glucose curve (Figure. 1B). Adding BZ043 to a commercial vial of GLAR at 0.1 or 0.5 mg/mL did not result in observable alteration of the average molecular radius of the samples after 24 weeks of incubation at 4 °C, as shown by dynamic light scattering (Figure. 1C). In STZ rats, BZ043 showed a prolonged anti-hyperglycemic effect and, together with GLAR, promoted a long-lasting normoglycemia, with flat variation of glycemia. While further investigation on the physicochemical stability of the combination is ongoing, our data suggest that BZ043 and glargine in a FC might improve the control of T1D in humans.

C.V.F. Nascimento: Employee; Self; Biozeus Biopharmaceutical S.A. P.G. Lacativa: Employee; Self; BIOZEUS Biopharmaceutical. F. Briand: Employee; Self; Physiogenex S.A.S.. Stock/Shareholder; Self; Physiogenex S.A.S. L.M.T. Lima: Research Support; Self; BioZeus.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at